BWAY Brainsway

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of . The National Alliance on Mental Illness (NAMI) organizes NAMIWalks Your Way events around the country each year to increase mental health awareness, build community, and help raise funds for programs. The Silicon Valley Walk will be Saturday, October 1, 2022.



“I am honored to be part of this extremely important event, which aligns with BrainsWay’s goal of raising awareness about mental illness and increasing access to mental health resources. I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk,” said Dr. von Jako.

He added, “NAMI Walks are wonderful opportunities to meet patients, families, and providers to hear their stories, and work together for a brighter future. I encourage everyone in Silicon Valley to participate in the Walk, taking steps as a community to improve mental healthcare for all.”

Rovina Nimbalkar, Executive Director of NAMI Santa Clara County, said, “We are honored to have Christopher von Jako as our honorary chair for NAMIWalks Silicon Valley and we are excited about our collaboration with BrainsWay. NAMIWalks Silicon Valley is our biggest fundraiser, and after two years we are going to walk in person. The last two years have been particularly difficult for people with a mental health diagnosis, and we walk to honor them and to create awareness for mental illness.”

The October 1 event will be in San Jose’s History Park from 9:00am – 1:00pm PST. In addition to Dr. von Jako, members of the mental health team of the San Francisco Giants will speak at the event, including Drew Robinson, Dr. Emily Payette, Minor League Mental Health Coordinator, and Dr. Shana Alexander, Director of Mental Health, Wellness, and EAP. NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness.

Click to register for the event.



About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Media Contact:

Meghan Laska

610-212-0125

 

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989



EN
20/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Compan...

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025 BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay’s growth strategy. The event will feature Owen Scott Muir, MD, DFAACA...

 PRESS RELEASE

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Al...

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder Multicenter, randomized, controlled study will evaluate Company’s next-generation multichannel TMS technology in reducing heavy drinking and cravings BURLINGTON, Mass. and JERUSALEM, Nov. 17, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced the launch of a multicenter clinical trial investigating the use of its novel Deep TMS 360™ system in individuals with Alcohol Use...

 PRESS RELEASE

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for M...

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21 Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted a label expansion for the D...

 PRESS RELEASE

BrainsWay Reports Third Quarter 2025 Financial Results and Operational...

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JE...

 PRESS RELEASE

BrainsWay Reports National Institutes of Health Grant to Leading U.S. ...

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder New NIH grant awards $2.5 million over 5 years for mechanistic study BURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded a new grant – totaling approximately $2.5 million over f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch